Trials / Unknown
UnknownNCT05338541
Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood.
Tucidinostat Plus Etoposide in the Treatment of Relapsed or Refractory Neuroblastoma in Children
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Yizhuo Zhang · Academic / Other
- Sex
- All
- Age
- 3 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
Neuroblastoma is a malignant tumor that develops in infants and kids. Dysregulation of histone acetylation is associated with a series of malignant tumors. Neuroblastoma is caused by defective neural crest differentiation due to abnormal gene regulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tucidinostat and etoposide | Tucidinostat: 3+3 design，14 mg/m2，17.5 mg/m2，23 mg/m2 etoposide: 50mg/m2, |
Timeline
- Start date
- 2022-05-27
- Primary completion
- 2024-06-30
- Completion
- 2024-12-01
- First posted
- 2022-04-21
- Last updated
- 2024-02-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05338541. Inclusion in this directory is not an endorsement.